A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 144
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IMDC
Long Form : International Metastatic Renal Cell Carcinoma Database Consortium
No. Year Title Co-occurring Abbreviation
2022 Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. CN, IPTW, OS, RCC
2021 Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. AEs, CI, HFSR, HR, ICIs, ITT, mRCC, ORR, OS, PFS, RCTs, RR, VEGFR
2021 C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. CRP, mccRCC, NLR, OS, PFS
2021 Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma? RCC, SII
2021 Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. BrM, mRCC, OS, PFS
2021 Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDCrisk groups in metastatic renal cell carcinoma: a meta-analysis. ICI, TKIs
2021 Development and internal validation of nomograms for the prediction of postoperative survival of patients with grade 4 renal cell carcinoma (RCC). AST, CSS, OS, PFS, RCC
2021 Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. ccRCC, CN, RCC
2021 Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. OS, RCC
10  2021 Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. CI, CN, HR, mRCC, OS
11  2021 First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ICI, mccRCC, TKI
12  2021 First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies? ICI, TKI, VEGF
13  2021 Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. CAF, ccRCC, IHC, NN, OS, OS-IT, OS-TT, PFS, ROI, TT
14  2021 Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). dNLR, LMR, mRCC, NLR, OS, PLR, SII, SIRI
15  2021 Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. ---
16  2021 Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. AEs, ITT, OS
17  2021 Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. CPI, mRCC, OS, PFS, TKI, TTD
18  2021 Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. mRCC, OS, PFS
19  2021 Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study. ECOG, FR, IR, mRCC, ORR, OS, PFS, PR, PS
20  2021 Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. CNS, mRCC
21  2021 Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. JMRC, MSKCC
22  2021 Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model. AIC, KRoCS, mRCC, MSKCC
23  2021 Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. AUC, mRCC, OS, RCC
24  2021 Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. MSKCC
25  2021 Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. AUCs, BNM, mRCC, OS, TRAE
26  2021 Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma. ICI
27  2021 Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. RCC, RRS
28  2021 Sarcopenia and modified Glasgow Prognostic Score predict postsurgical outcomes in localized renal cell carcinoma. CSS, mGPS, OS, RCC, RFS, ROC, SMI, SSIGN
29  2021 Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma. ccRCC, IHC, MASS, PD-1
30  2021 Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study. CI, IQR, PFS, RCC, TKI, VEGF
31  2021 Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? CN, HR, mRCC, OS, SOC
32  2021 Synchronous brain metastases as a poor prognosis factor in clear cell renal carcinoma: a strong argument for systematic brain screening. B-PFS, BM, ccRCC, OS, RCC, SRT, WBRT
33  2021 The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. ICI, ORR, OS, PFS
34  2021 The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. IPW, OS, PNI, PSM, PSTs, RCC
35  2021 The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. mRCC, OS, PFS, RDW
36  2021 THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy. mRCC, OS, PFS, RCC, THSD7A
37  2021 Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study. AEs, HFS, PFS, RCC
38  2021 Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. ccRCC, dCN, MTS, OS, PTS, RCC, TMT
39  2020 Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. mRCC, OS
40  2020 Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors. BM, m-papRCC, mOS, mPFS, papRCC, PFS and OS, VEGFR-TKIs
41  2020 Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy. ACN, ALB, CRP, mRCC, MSKCC, NLR, OS
42  2020 Exploration of IMDC model in patients with metastatic renal cell carcinoma using targeted agents: a meta-analysis. PRISMA
43  2020 First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. CI, CRP, HR, mRCC, OS, PFS
44  2020 Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. CART, ccRCC, IR, OS
45  2020 Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ICI, mccRCC, SARS-CoV-2, TKI
46  2020 Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. mRCC, OS, SII
47  2020 Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. ICI, RCC, TKIs, VEGF, VEGFR
48  2020 Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. BMI, CI, ICIs, MLR, mRCC, OS
49  2020 Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. HR, mRCC, OS, PFS, TKIs, TTF, UM
50  2020 Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. CI, CNS, OS, RCC
51  2020 Prognostic Importance of Metastatic Site in Intermediate-risk Group Metastatic Renal Cell Cancer Treated with Tyrosine Kinase Inhibitors. mRCC, OS
52  2020 Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma. mRCC, OS
53  2020 Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. mRCC, OS, TTD
54  2020 Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. ORR, OS, PFS, RCC, TTF, TTP
55  2020 Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. mRCC, OS
56  2020 Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. CI, mRCC, NE
57  2020 Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. CI, CN, mRCC, MSKCC, SSIGN, UISS
58  2020 Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. aRCC, ITT, ORR, OS, PFS, SUN
59  2020 Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. mRCC, MVAs, OS, TKIs, TTF
60  2020 The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma mRCC, NLR, NLR, OS, PLR, TKI
61  2020 Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. CN, mccRCC, VEGFR-TKIs
62  2020 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma. IO, OS, PFS, RCC
63  2020 Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. LR, MDACC, mRCC, OS, PFS, RMH, TP
64  2019 Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. CI, HR, ORR, OS, PFS, RCC
65  2019 C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. CN, CN-sunitinib, mRCC, OS, PFS
66  2019 Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. IRC, ORR, PFS, RCC
67  2019 Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. accRCC, PFS, RR
68  2019 Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. CI, CN, HR, mRCC, OS, PFS
69  2019 Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? BTTs, CI, HR, mRCC, OS, SREs, TKIs
70  2019 Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. HR, ORR, OS, PFS
71  2019 First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. CI, IO, IOVE, ipi-nivo, mRCC, OS, TNT, TTF, VEGF
72  2019 First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options. mRCC, VEGF
73  2019 Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma. MSKCC
74  2019 Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. CI, HR, mRCC, OS
75  2019 Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. IMPACT, mccRCC
76  2019 Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. aRCC, CI, HR, ITT, ORR, OS, PFS, SUN
77  2019 Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors. mRCC, TKIs
78  2019 Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. HD IL-2, mRCC, OS
79  2019 Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx. CI, mRCC, OS, PFS, VEGFR
80  2019 Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. CRP, HR, mOS, NLR, OS
81  2019 Prognostic value of serum C-reactive protein level prior to second-line treatment in intermediate risk metastatic renal cell carcinoma patients. CRP, mRCC, OS
82  2019 Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. CI, MSKCC, PS
83  2019 Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. CI, HR, mRCC, orrs, OS, TTF
84  2019 Response of Primary Renal Cell Carcinoma to Systemic Therapy. CRN, ORR, RCC, RECIST, VEGF
85  2019 Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. ICIs, mRCC, TT, VEGFR
86  2019 Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. CI, HR, ISUP, mRCC, OS, PFS, SPF, TNM
87  2019 Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma. BM, mRCC, SRS
88  2019 Surgery for high-risk locally advanced (pT3c) renal tumours: oncological outcomes and prognostic significance of a modified International Metastatic Renal Cell Cancer Database Consortium (IMDC) score. IQR, OS
89  2019 Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. CI, HR, ORR, OS, PFS, PROs, TemPa, VEGFR-TKI
90  2019 The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. CN, HR, MSK, OS, RCC
91  2019 The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. C-index, MSKCC, NLR, RCC
92  2019 Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study. CRP, IPTW, OS
93  2019 [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma]. ---
94  2018 A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. mRCC, QoL, SABR
95  2018 Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry. CSS, mNCCRCC, MSKCC, PFS, RCC
96  2018 Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma. ESAS, mRCC
97  2018 Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. DOT, IO, mRCC, ORRs, OS, PD-L1
98  2018 Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. aRCC, AUC, MSKCC, RCC, ROC
99  2018 Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma. RCC
100  2018 Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience. CI, HFS, mRCC, MSKCC, OS, PFS, ULN